Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117


A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.

Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenaeinen I, Petrovic K, Johnson BE.

Ann Oncol. 2014 Feb;25(2):505-11. doi: 10.1093/annonc/mdt535. Epub 2013 Dec 23.


Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.

Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V.

Invest New Drugs. 2014 Feb;32(1):123-34. doi: 10.1007/s10637-013-9958-3. Epub 2013 Apr 12.


Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.

Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.

Clin Lung Cancer. 2003 Jul;5(1):40-5.


Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.

William WN Jr, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS.

Cancer. 2010 May 15;116(10):2409-15. doi: 10.1002/cncr.25076.


A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.

Ellis PM, Jungnelius U, Zhang J, Fandi A, Beck R, Shepherd FA.

J Thorac Oncol. 2013 Apr;8(4):423-8. doi: 10.1097/JTO.0b013e318282707b.


A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J.

Clin Drug Investig. 2006;26(5):257-66.


A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.

Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA Jr.

Clin Cancer Res. 1999 Nov;5(11):3419-24.


Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.

Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Di Scala L, Pylvaenaeinen I, Petrovic K, Dimitrijevic S, Anrys B, Laack E.

J Thorac Oncol. 2011 Dec;6(12):2120-9. doi: 10.1097/JTO.0b013e3182307ede.


A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).

Owonikoko TK, Dahlberg SE, Khan SA, Gerber DE, Dowell J, Moss RA, Belani CP, Hann CL, Aggarwal C, Ramalingam SS.

Lung Cancer. 2015 Jul;89(1):66-70. doi: 10.1016/j.lungcan.2015.04.015. Epub 2015 May 8.


A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.

Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V; Greek Lung Cancer Cooperative Group..

Ann Oncol. 2001 Apr;12(4):463-70.


Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.

Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, et al.

J Clin Oncol. 1994 Oct;12(10):2022-34.


NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.

Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo M, Powers J, Seymour L, Bradbury PA.

J Thorac Oncol. 2014 Mar;9(3):410-3. doi: 10.1097/JTO.0000000000000058.


[Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].

You J, Yu H, Song M, Shi C, Wang X, Zheng Y, Yu R, Shi A, Zhu G.

Zhongguo Fei Ai Za Zhi. 2017 Jan 20;20(1):55-60. doi: 10.3779/j.issn.1009-3419.2017.01.08. Chinese.


Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.

Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V; Hellenic Oncology Research Group..

Lung Cancer. 2002 Oct;38(1):59-63.


Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.

De Marinis F, Migliorino MR, Paoluzzi L, Portalone L, Ariganello O, Cortesi E, Gamucci T, Gasperoni S, Cipri A, Martelli O, Nelli F; Foundation for Oncological Research..

Lung Cancer. 2003 Mar;39(3):331-8.


Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, Angokai M, Bahleda R, Deandreis D, Angevin E, Hennequin C, Besse B, Levy A, Soria JC.

Ann Oncol. 2015 Jun;26(6):1223-9. doi: 10.1093/annonc/mdv105. Epub 2015 Feb 20.


Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.

Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK.

Cancer. 1998 Jan 15;82(2):301-8.


A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.

Cancer. 2002 Oct 1;95(7):1511-9.


Supplemental Content

Support Center